Raw Materials powder Empagliflozin

CAS:864070-44-0

MF:C23H27ClO7

MW:450.91

EINECS:620-176-8

Specification​: 99% min Empagliflozin powder

Sample:Empagliflozin powder

Packaging:1kg/bag, 25kg/drum

Brand: Henrikang

Appearance:white

Storage: Cool Dry Place

Shelf Life: 2 Years

Test Method: HPLC

Empagliflozin powder Usage and Synthesis.

Epalliprazin is indicated for the treatment of adults with diabetes who do not achieve adequate glycemic control with diet combined with exercise to improve glycemic control. It should not be used to treat patients with type 1 diabetes, elevated ketones in the blood or urine (diabetic ketoacidosis), severe kidney damage, end-stage kidney disease, and dialysis.

Uses of Empagliflozin.

Englazine tablets have hypoglycemic properties and are suitable for the treatment of type 2 diabetes by promoting the excretion of glucose from the urine. In addition to lowering blood sugar, it also has a certain protective effect on the heart and kidneys.

Englliquine is a highly selective SGLT2 inhibitor with protective effects on cardiovascular and renal function. Currently, SGLT2 inhibitors have been widely recommended as hypoglycemic agents in diabetes treatment guidelines. It has a unique insulin-independent hypoglycemic pathway, that is, directly excreting sugar from the urine by reducing the reabsorption of glucose in the kidneys.

In addition to having a clear hypoglycemic effect, it can also bring additional effects of weight loss, blood pressure, and uric acid reduction. Englizin has a better safety profile and can reduce the risk of cardiovascular events and kidney disease progression in diabetic patients. This product can cause a decrease in blood volume. Symptomatic hypotension may occur after the use of this product, especially in patients with kidney damage, the elderly, patients with low systolic blood pressure and patients receiving diuretics. Before starting the use of this product, the blood volume should be evaluated for decrease, if there is a decrease in blood volume, the volume status should be corrected. After starting treatment, the signs and symptoms of hypotension should be monitored, and monitoring should be increased in clinical situations where a decrease in blood volume is expected.

Pharmacological action of Empagliflozin.

Under physiological environment, the kidney filters and reabsorbs glucose into the circulatory system to maintain the blood glucose balance in the body, while glucose enters the blood through the renal tubule lumen with the cooperation of glucose cotransport protein. SGLT2, as a form of sodium and glucose cotransport protein in glucose cotransport protein, blocks the reabsorption of glucose by the proximal convoluted tubules. Reduces glucose reabsorption by the kidneys and increases the excretion of glucose in the urine, thereby reducing plasma glucose levels. The hypoglycemic effect did not depend on the function of beta cells and was not affected by insulin resistance.

Product method of Bulk Empagliflozin.